Cell

, volume 185 , issue 12 , pages 2103-2115.e19

Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike

Daichi Yamasoba ^{1, 2}

Izumi Kimura ¹

Hesham Nasser ^{3, 4}

Yuhei Morioka ⁵

Naganori Nao ^{6, 7}

Jumpei Ito ¹

Keiya Uriu ¹

Masumi Tsuda ⁸

Jiří Zahradník ⁹

Kotaro Shirakawa ¹⁰

Rigel Suzuki ⁵

Mai Kishimoto ¹¹

Yusuke Kosugi ^{1, 12, 13}

Kouji Kobiyama ¹⁴

Teppei Hara ¹⁴

Mako Toyoda ¹⁵

Yuri L Tanaka ¹⁶

Erika P Butlertanaka ¹⁶

Ryo Shimizu ⁴

Hayato Ito ⁵

Lei Wang ⁸

Yoshitaka Oda ⁸

HIROFUMI SAWA ^{11, 16}

Michihito Sasaki ¹¹

Kayoko Nagata ¹⁰

Kumiko Yoshimatsu ¹⁷

Hiroyuki Asakura ¹⁸

Mami Nagashima ¹⁸

Kenji Sadamasu ¹⁸

Kazuhisa Yoshimura ¹⁸

Jin Kuramochi ¹⁹

Motoaki Seki ²⁰

Ryoji Fujiki ²⁰

Atsushi Kaneda ²⁰

Tadanaga Shimada ²¹

Taka-aki Nakada ²¹

Seiichiro Sakao ²²

Takuji Suzuki ²²

Takamasa Ueno ¹⁵

Akifumi Takaori-Kondo ¹⁰

Ken Ishii ¹⁴

Gideon Schreiber ⁹

Hirofumi Sawa ^{6, 7}

Akatsuki Saito ¹⁶

Takashi Irie ²³

Shinya Tanaka ⁸

Keita Matsuno ⁷

Takasuke Fukuhara ⁵

Terumasa Ikeda ⁴

Kei Sato ^{1, 24, 25}

Hide authors affiliations Show authors affiliations: 25 affiliations

Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan |

Faculty of Medicine, Kobe University, Kobe, Japan |

Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt |

⁴

Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan |

⁵

Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan |

⁶

Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan |

⁷

One Health Research Center, Hokkaido University, Sapporo, Japan |

⁸

Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan |

⁹

Department of Biomolecular sciences, Weizmann Institute of Science, Rehovot, Israel |

¹⁰

Department of Hematology and Oncology, Graduate school of medicine, Kyoto University, Kyoto, Japan |

¹¹

Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan |

¹²

Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan |

¹³

Laboratory of Systems Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan |

¹⁴

Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan |

¹⁵

Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan |

¹⁶

Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan |

¹⁷

Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan |

¹⁸

Tokyo Metropolitan Institute of Public Health, Tokyo, Japan |

¹⁹

Interpark Kuramochi Clinic, Utsunomiya, Japan |

²⁰

Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan |

²¹

Department of Emergency and Critical Care Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan |

²²

Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan |

²³

Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan |

²⁴

CREST, Japan Science and Technology agency, Kawaguchi, Japan |

²⁵

International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan |

Publication type: Journal Article

Publication date: 2022-06-01

Elsevier

Cell

scimago Q1

wos Q1

SJR: 22.612

CiteScore: 74.8

Impact factor: 42.5

ISSN: 00928674, 10974172

DOI: 10.1016/j.cell.2022.04.035

Copy DOI

PubMed ID: 35568035

General Biochemistry, Genetics and Molecular Biology

Abstract

Summary

Soon after the emergence and global spread of the SARS-CoV-2 Omicron lineage BA.1, another Omicron lineage, BA.2, began outcompeting BA.1. The results of statistical analysis showed that the effective reproduction number of BA.2 is 1.4-fold higher than that of BA.1. Neutralization experiments revealed that immunity induced by COVID vaccines widely administered to human populations is not effective against BA.2, similar to BA.1, and that the antigenicity of BA.2 is notably different from that of BA.1. Cell culture experiments showed that the BA.2 spike confers higher replication efficacy in human nasal epithelial cells and is more efficient in mediating syncytia formation than the BA.1 spike. Furthermore, infection experiments using hamsters indicated that the BA.2 spike-bearing virus is more pathogenic than the BA.1 spike-bearing virus. Altogether, the results of our multiscale investigations suggest that the risk of BA.2 to global health is potentially higher than that of BA.1.

Found

3 citations

Tanaka Shinya

93 publications, 2 113 citations, 1 review

h-index: 19

Hokkaido University

Hokkaido University Hospital

Nagoya University

Tokyo University of Marine Science and Technology

Research interests

Biomedical engineering

1 citation

Yusubalieva Gaukhar

🥼 🤝

PhD in Health sciences

84 publications, 925 citations

h-index: 16

Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences

Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency of Russia

Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies, FMBA of Russia

Research interests

Brain stem cells

CAR-NK cells

Experimental oncology

Immunotherapy

Oncolytic viruses

1 citation

Xu H. Eric

PhD

725 publications, 21 211 citations, 8 reviews

h-index: 71

Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Top-30

Journals

	2 4 6 8 10 12
Nature Communications	Nature Communications, 12, 4% Nature Communications 12 publications, 4%
Viruses	Viruses, 12, 4% Viruses 12 publications, 4%
The Lancet Infectious Diseases	The Lancet Infectious Diseases, 9, 3% The Lancet Infectious Diseases 9 publications, 3%
Journal of Medical Virology	Journal of Medical Virology, 8, 2.67% Journal of Medical Virology 8 publications, 2.67%
Cell Host and Microbe	Cell Host and Microbe, 7, 2.33% Cell Host and Microbe 7 publications, 2.33%
iScience	iScience, 7, 2.33% iScience 7 publications, 2.33%
Journal of Virology	Journal of Virology, 6, 2% Journal of Virology 6 publications, 2%
Emerging Microbes & Infections	Emerging Microbes & Infections, 6, 2% Emerging Microbes & Infections 6 publications, 2%
Frontiers in Immunology	Frontiers in Immunology, 5, 1.67% Frontiers in Immunology 5 publications, 1.67%
Frontiers in Medicine	Frontiers in Medicine, 5, 1.67% Frontiers in Medicine 5 publications, 1.67%
PLoS Pathogens	PLoS Pathogens, 5, 1.67% PLoS Pathogens 5 publications, 1.67%
EBioMedicine	EBioMedicine, 5, 1.67% EBioMedicine 5 publications, 1.67%
Microbiology spectrum	Microbiology spectrum, 4, 1.33% Microbiology spectrum 4 publications, 1.33%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 4, 1.33% International Journal of Molecular Sciences 4 publications, 1.33%
Vaccines	Vaccines, 4, 1.33% Vaccines 4 publications, 1.33%
Antiviral Research	Antiviral Research, 4, 1.33% Antiviral Research 4 publications, 1.33%
International Journal of Infectious Diseases	International Journal of Infectious Diseases, 4, 1.33% International Journal of Infectious Diseases 4 publications, 1.33%
Scientific Reports	Scientific Reports, 4, 1.33% Scientific Reports 4 publications, 1.33%
bioRxiv	bioRxiv, 4, 1.33% bioRxiv 4 publications, 1.33%
mBio	mBio, 4, 1.33% mBio 4 publications, 1.33%
Frontiers in Microbiology	Frontiers in Microbiology, 3, 1% Frontiers in Microbiology 3 publications, 1%
Frontiers in Virology	Frontiers in Virology, 3, 1% Frontiers in Virology 3 publications, 1%
Virology Journal	Virology Journal, 3, 1% Virology Journal 3 publications, 1%
Communications Medicine	Communications Medicine, 2, 0.67% Communications Medicine 2 publications, 0.67%
Nature	Nature, 2, 0.67% Nature 2 publications, 0.67%
Signal Transduction and Targeted Therapy	Signal Transduction and Targeted Therapy, 2, 0.67% Signal Transduction and Targeted Therapy 2 publications, 0.67%
Communications Biology	Communications Biology, 2, 0.67% Communications Biology 2 publications, 0.67%
Journal of Biomedical Science	Journal of Biomedical Science, 2, 0.67% Journal of Biomedical Science 2 publications, 0.67%
Cell Discovery	Cell Discovery, 2, 0.67% Cell Discovery 2 publications, 0.67%
	2 4 6 8 10 12

Publishers

	10 20 30 40 50 60 70
Elsevier	Elsevier, 65, 21.67% Elsevier 65 publications, 21.67%
Springer Nature	Springer Nature, 45, 15% Springer Nature 45 publications, 15%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 42, 14% Cold Spring Harbor Laboratory 42 publications, 14%
MDPI	MDPI, 30, 10% MDPI 30 publications, 10%
Frontiers Media S.A.	Frontiers Media S.A., 19, 6.33% Frontiers Media S.A. 19 publications, 6.33%
Wiley	Wiley, 17, 5.67% Wiley 17 publications, 5.67%
American Society for Microbiology	American Society for Microbiology, 15, 5% American Society for Microbiology 15 publications, 5%
Taylor & Francis	Taylor & Francis, 8, 2.67% Taylor & Francis 8 publications, 2.67%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 5, 1.67% Public Library of Science (PLoS) 5 publications, 1.67%
Oxford University Press	Oxford University Press, 5, 1.67% Oxford University Press 5 publications, 1.67%
American Association for the Advancement of Science (AAAS)	American Association for the Advancement of Science (AAAS), 4, 1.33% American Association for the Advancement of Science (AAAS) 4 publications, 1.33%
Research Square Platform LLC	Research Square Platform LLC, 4, 1.33% Research Square Platform LLC 4 publications, 1.33%
American Chemical Society (ACS)	American Chemical Society (ACS), 3, 1% American Chemical Society (ACS) 3 publications, 1%
Walter de Gruyter	Walter de Gruyter, 2, 0.67% Walter de Gruyter 2 publications, 0.67%
F1000 Research	F1000 Research, 2, 0.67% F1000 Research 2 publications, 0.67%
Royal Society of Chemistry (RSC)	Royal Society of Chemistry (RSC), 2, 0.67% Royal Society of Chemistry (RSC) 2 publications, 0.67%
IntechOpen	IntechOpen, 2, 0.67% IntechOpen 2 publications, 0.67%
Massachusetts Medical Society	Massachusetts Medical Society, 1, 0.33% Massachusetts Medical Society 1 publication, 0.33%
Centers for Disease Control and Prevention (CDC)	Centers for Disease Control and Prevention (CDC), 1, 0.33% Centers for Disease Control and Prevention (CDC) 1 publication, 0.33%
American Society for Clinical Investigation	American Society for Clinical Investigation, 1, 0.33% American Society for Clinical Investigation 1 publication, 0.33%
Pleiades Publishing	Pleiades Publishing, 1, 0.33% Pleiades Publishing 1 publication, 0.33%
European Molecular Biology Organization	European Molecular Biology Organization, 1, 0.33% European Molecular Biology Organization 1 publication, 0.33%
Eco-Vector LLC	Eco-Vector LLC, 1, 0.33% Eco-Vector LLC 1 publication, 0.33%
Cambridge University Press	Cambridge University Press, 1, 0.33% Cambridge University Press 1 publication, 0.33%
Microbiology Society	Microbiology Society, 1, 0.33% Microbiology Society 1 publication, 0.33%
The Japanese Society on Thrombosis and Hemostasis	The Japanese Society on Thrombosis and Hemostasis, 1, 0.33% The Japanese Society on Thrombosis and Hemostasis 1 publication, 0.33%
SAGE	SAGE, 1, 0.33% SAGE 1 publication, 0.33%
Bentham Science Publishers Ltd.	Bentham Science Publishers Ltd., 1, 0.33% Bentham Science Publishers Ltd. 1 publication, 0.33%
SciELO	SciELO, 1, 0.33% SciELO 1 publication, 0.33%
	10 20 30 40 50 60 70

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

301

Cite this

GOST |

Cite this

GOST Copy

Yamasoba D. et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike // Cell. 2022. Vol. 185. No. 12. p. 2103-2115.e19.

GOST all authors (up to 50) Copy

Yamasoba D. et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike // Cell. 2022. Vol. 185. No. 12. p. 2103-2115.e19.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1016/j.cell.2022.04.035

UR - https://doi.org/10.1016/j.cell.2022.04.035

TI - Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike

T2 - Cell

AU - Yamasoba, Daichi

AU - Kimura, Izumi

AU - Nasser, Hesham

AU - Morioka, Yuhei

AU - Nao, Naganori

AU - Ito, Jumpei

AU - Uriu, Keiya

AU - Tsuda, Masumi

AU - Zahradník, Jiří

AU - Shirakawa, Kotaro

AU - Suzuki, Rigel

AU - Kishimoto, Mai

AU - Kosugi, Yusuke

AU - Kobiyama, Kouji

AU - Hara, Teppei

AU - Toyoda, Mako

AU - Tanaka, Yuri L

AU - Butlertanaka, Erika P

AU - Shimizu, Ryo

AU - Ito, Hayato

AU - Wang, Lei

AU - Oda, Yoshitaka

AU - SAWA, HIROFUMI

AU - Sasaki, Michihito

AU - Nagata, Kayoko

AU - Yoshimatsu, Kumiko

AU - Asakura, Hiroyuki

AU - Nagashima, Mami

AU - Sadamasu, Kenji

AU - Yoshimura, Kazuhisa

AU - Kuramochi, Jin

AU - Seki, Motoaki

AU - Fujiki, Ryoji

AU - Kaneda, Atsushi

AU - Shimada, Tadanaga

AU - Nakada, Taka-aki

AU - Sakao, Seiichiro

AU - Suzuki, Takuji

AU - Ueno, Takamasa

AU - Takaori-Kondo, Akifumi

AU - Ishii, Ken

AU - Schreiber, Gideon

AU - Sawa, Hirofumi

AU - Saito, Akatsuki

AU - Irie, Takashi

AU - Tanaka, Shinya

AU - Matsuno, Keita

AU - Fukuhara, Takasuke

AU - Ikeda, Terumasa

AU - Sato, Kei

PY - 2022

DA - 2022/06/01

PB - Elsevier

SP - 2103-2115.e19

IS - 12

VL - 185

PMID - 35568035

SN - 0092-8674

SN - 1097-4172

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2022_Yamasoba,

author = {Daichi Yamasoba and Izumi Kimura and Hesham Nasser and Yuhei Morioka and Naganori Nao and Jumpei Ito and Keiya Uriu and Masumi Tsuda and Jiří Zahradník and Kotaro Shirakawa and Rigel Suzuki and Mai Kishimoto and Yusuke Kosugi and Kouji Kobiyama and Teppei Hara and Mako Toyoda and Yuri L Tanaka and Erika P Butlertanaka and Ryo Shimizu and Hayato Ito and Lei Wang and Yoshitaka Oda and HIROFUMI SAWA and Michihito Sasaki and Kayoko Nagata and Kumiko Yoshimatsu and Hiroyuki Asakura and Mami Nagashima and Kenji Sadamasu and Kazuhisa Yoshimura and Jin Kuramochi and Motoaki Seki and Ryoji Fujiki and Atsushi Kaneda and Tadanaga Shimada and Taka-aki Nakada and Seiichiro Sakao and Takuji Suzuki and Takamasa Ueno and Akifumi Takaori-Kondo and Ken Ishii and Gideon Schreiber and Hirofumi Sawa and Akatsuki Saito and Takashi Irie and Shinya Tanaka and Keita Matsuno and Takasuke Fukuhara and Terumasa Ikeda and Kei Sato and others},

title = {Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike},

journal = {Cell},

year = {2022},

volume = {185},

publisher = {Elsevier},

month = {jun},

url = {https://doi.org/10.1016/j.cell.2022.04.035},

number = {12},

pages = {2103--2115.e19},

doi = {10.1016/j.cell.2022.04.035}

}

MLA

Cite this

MLA Copy

Yamasoba, Daichi, et al. “Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike.” Cell, vol. 185, no. 12, Jun. 2022, pp. 2103-2115.e19. https://doi.org/10.1016/j.cell.2022.04.035.

Publisher

Elsevier

Journal

Cell

scimago Q1

wos Q1

SJR

22.612

CiteScore

74.8

Impact factor

42.5

ISSN

00928674 (Print)

10974172 (Electronic)

Profiles